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Background: The Wnt inhibitor Dickkopf-1 (DKK-1) has been linked to the progression of malignant bone disease
by impairing osteoblast activity. In addition, there is increasing data to suggest direct tumor promoting effects of
DKK-1. The prognostic role of DKK-1 expression in prostate cancer remains unclear.
Methods: A prostate cancer tissue microarray (n = 400) was stained for DKK-1 and DKK-1 serum levels were
measured in 80 patients with prostate cancer. The independent prognostic value of DKK-1 expression was
assessed using multivariate analyses.
Results: DKK-1 tissue expression was significantly increased in prostate cancer compared to benign disease, but
was not correlated with survival. However, high DKK-1 serum levels at the time of the diagnosis were associated
with a significantly shorter overall and disease-specific survival. Multivariate analyses defined high serum levels
of DKK-1 as an independent prognostic marker in prostate cancer (HR 3.73; 95%CI 1.44-9.66, p = 0.007).
Conclusion: High DKK-1 serum levels are associated with a poor survival in patients with prostate cancer. In
light of current clinical trials evaluating the efficacy of anti-DKK-1 antibody therapies in multiple myeloma and
solid malignancies, the measurement of DKK-1 in prostate cancer may gain clinical relevance.
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Prostate cancer is the most common cancer in men,
and patients with advanced disease frequently develop
bone metastases [1]. In bone, osteoblast functions are
dependent on canonical Wnt signalling [2]. This process
is controlled by Wnt inhibitors, including sclerostin and
dickkopf-1 (DKK-1) [3]. Elevated levels of DKK-1 pro-
mote bone lesions in multiple myeloma and breast can-
cer by inhibiting osteoblast activity [4-6]. The clinical
efficacy of DKK-1 inhibition is currently tested in pa-
tients with multiple myeloma [7]. The role of DKK-1 in
prostate cancer, however, is less clear. DKK-1 tissue
expression has been described to increase in primary
prostate cancer lesions compared to normal tissue, and
high DKK-1 levels within prostate cancer metastases* Correspondence: tilman.rachner@uniklinikum-dresden.de
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unless otherwise stated.were associated with poor survival [8]. Furthermore, in a
murine model of prostate cancer, DKK-1 stimulated
subcutaneous tumour growth and bone metastasis [9].
By contrast, knock-down of DKK-1 delayed the develop-
ment of both soft tissue and osseous prostate cancer
lesions [10]. These findings suggest that DKK-1 may
have an impact on cancer biology beyond its role in
malignant bone disease. Here, we assessed the role of
DKK-1 expression in tissues and sera from patients
with prostate cancer and evaluated its prognostic value
in affected patients.Methods
Tissue microarray
A prostate cancer tissue microarray (TMA) was gener-
ated from patients of clinically diagnosed and histologi-
cally confirmed prostate cancer who underwent a radical
prostatectomy at the TU Dresden Medical Center of
Dresden between 1996 and 2005. A total of 400 prostatel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tate hyperplasia (BPH) were included. Patients with high
risk prostate cancer (high Gleason score and/or lymph
node metastasis) were included at a higher rate than
their incidence rate for the evaluation of prognostic as-
sociations. At the time of prostatectomy and serum sam-
pling all patients included in this study were free of
clinically detectable bone lesions or other distant metas-
tasis. TMA slides were designed to include cancer tissue
from 4 different locations and 2 samples from adjacent
non-tumour tissue from each patient. Slides included in-
ternal controls to ensure staining reproducibility be-
tween slides. Patient characteristics are listed in Table 1.
All tissue samples were obtained, stored and assessed
under the same conditions as approved by the Institu-
tional Review Board (institutional review board of the
TU Dresden). Written informed consent was obtained
from all patients. Histological processing was per-
formed in the accredited Department of Pathology and
conducted using a standardized procedure to assure
reproducibility.
Immunohistochemistry (IHC)
DKK-1 tissue protein levels were assessed using IHC as
previously described [6]. Briefly, 2 μm-thick paraffin sec-
tions were dewaxed, rehydrated using an alcohol gradi-
ent, and heat-treated for antigen retrieval. Endogenous
peroxidase activity was blocked using 0.3% H2O2/PBS
for 10 min at room temperature and non-specific bind-
ing sites using the blocking buffer of the VECTASTAIN
Elite ABC Kit (VECTOR Laboratories, Peterborough,
UK) for 45 min. Sections were incubated with an anti-
DKK-1 antibody (ab22827; Abcam, Milton, UK) over-
night at 4°C. Subsequently, slides were treated with an
anti-goat secondary antibody conjugated to biotin andTable 1 Patient characteristics of TMA
Characteristics Median (IQR) or Frequency (%)
Age at diagnosis (years) 65 (61, 68)
Preoperative PSA (ng/ml) 8.6 (5.54, 15.71)








< 7 78 (19.50)
= 7 75 (18.75)
> 7 247 (61.75)developed utilizing avidin-conjugated HRP with diami-
niobenzidine (DAKO). Specificity of the antibody has
been previously validated [6]. TMAs were assessed by
two experienced scientists. Staining intensity was scored
as either absent (0), weak (1), moderate (2) or strong (3).
Unless otherwise specified staining score is presented as
the mean value of the 4 tumour or 2 adjacent normal
samples from each patient.
DKK-1 ELISA
Serum samples were available from 80 of the 400 pa-
tients included on the TMA. All serum samples were
obtained after informed consent and IRB approval at the
time of diagnosis, prior to prostatectomy and pharmaco-
logical treatment of the disease. Serum samples were
stored under the same conditions at −80°C until use. Pa-
tient characteristics are listed in Table 2. Human DKK-1
ELISA was provided by Biomedica (Vienna, Austria) and
performed according to the manufacturer’s instructions.
Twenty μl of serum were incubated with 50 μl of biotinyl-
ated DKK-1 antibody for 2 hours at room temperature.
Following repeated washing steps, 100 μl of conjugate
were added into each well and incubated for 1 hour. After
another washing step, substrate was added for 30 minutes
and absorbance was measured at 450 nm with reference
at 630 nm.
Ethical approval
All human samples used in this project (serum and tis-
sue) were obtained following informed patient consent
and approval of the institutional review board of the TU
Dresden (EK195092004).
Statistical analysis
DKK-1 protein expression in prostatic tissues is pre-
sented as the mean score of all available tissue spots
from each individual. Groups of two were assessed by
the Mann–Whitney-U-Test, groups of three or more
were assessed by ANOVA. Correlation was determined
by using the Spearman's rank correlation coefficient.
Serum and TMA samples were divided into two groups
at the DKK-1 median and classified as high or low DKK-
1. Kaplan Meier curves were assessed using the log-rank
(Mantel-Cox) test. Disease-specific survival (DSS) was
defined as time between surgery of the primary tumour
and death of disease or time of last follow-up. For over-
all survival (OS), death of any cause or time of last
follow-up was considered as endpoint. Univariate Cox
regression was performed on each clinical covariate to
examine its impact on survival. Multivariate analyses
were performed in a step-wise addition of covariates sig-
nificant in the univariate analyses. P values < 0.05 were
considered statistically significant.
Table 2 Clinical features of patients following division into groups according to DKK-1 serum levels (low vs. high)
Low DKK-1 (n = 40) High DKK-1 (n = 40)
Mean ± SD Median Mean ± SD Median p-Value
DKK-1 (pmol/l) 16.18 ± 7.5 14.69 38.44 ± 7.24 38.07 <0.01
Follow up (years) 8.56 ± 2.77 8.28 8.26 ± 3.29 8.9 n.s.
Age (years) 65.03 ± 4.40 64.99 65.27 ± 5.66 64.98 n.s.
PSA (ng/ml) 14.35 ± 13.27 8.88 9.86 ± 8.98 7.21 n.s.
n (%) n (%) p-Value
Tumour staging n.s.
pT2 17 (21.3%) 18 (22.5%)
pT3/4 23 (28.8%) 22 (27.5%)
Gleason score n.s.
< 7 15 (18.8%) 15 (18.8%)
= 7 14 (17.5%) 12 (15.0%)
> 7 11 (13.8%) 13 (16.3%)
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DKK-1 protein levels are increased in prostate cancer tissue
DKK-1 tissue expression was assessed in the prostate can-
cer TMA (Figure 1A). Of note, DKK-1 expression was very
heterogeneous with a great variability of DKK-1 staining in-
tensity within samples from one patient. The mean DKK-1
staining score in BPH was 0.79 ± 0.57. DKK-1 expression in



























Figure 1 DKK-1 tissue expression in prostate cancer. A) The prostate T
of each staining intensity (0–3) are shown. B) Distribution of DKK-1 expr
adjacent non-tumor tissue (A) is shown by boxplots. *DKK-1 tissue expre
BPH tissues (p < 0.0001). C) Kaplan Meier survival analyses for PCa patien
into high and low DKK-1 expression revealed no significant differences iscore 1.4 ± 0.55, p < 0.0001) compared to BPH, with no
differences between different tumour stages. Increased
DKK-1 expression was also observed in non-tumour tissue
adjacent to the tumour. There was no apparent difference
between the mean DKK-1 scores of malignant and adjacent
normal cells (Figure 1B + Additional file 1: Figure S1d).
DKK-1 levels were significantly lower in patients with con-
firmed lymph node involvement (Additional file 1: Figure2 3
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ts on the TMA dichotomized according to the median DKK-1 scores
n overall survival (log-rank test: p = 0.27).
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Figure 2 Kaplan-Meier survival curves of prostate cancer patients showing A) DSS and B) OS in relation to their DKK-1 serum levels.
Groups were dichotomised at the median into high and low DKK-1 serum levels. Statistical assessment was performed using the log-rank
(Mantel-Cox) test.
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expression and clinicopathological parameters such as
Gleason score, preoperative PSA serum levels and age
(Additional file 1: Figure S1b + d-f). Furthermore, there was
no correlation between tumour DKK-1 (high vs. low) and
patient overall (OS) (Figure 1C) or disease specific survival
(DSS) (data not shown).
High DKK-1 serum levels are associated with a poor sur-
vival in prostate cancer
We next assessed DKK-1 serum levels in 80 prostate
cancer patients that were available from patients in-
cluded on the TMA. Patients were divided into two
groups (high vs. low) according to the median DKK-1
serum level. There were no significant differences re-
garding other known patient characteristics between the
two groups (Table 2). Mean DKK-1 serum levels of all
patients was 27.9 ± 12.9 pmol/l. DKK-1 serum levels did
not correlate with the DKK-1 tissue scores in the cancerTable 3 Uni- and multivariate Cox regression analyses for clin
survival in patients with prostate cancer
Variables
Univariate analyses
HR 95% CI P v
Age (years) 1.04 0.96-1.13 0
pT (pT3/4 vs. pT2) 11.30 2.64-48.45 0.0
pN (pN1 vs. pN0) 2.89 1.19-7.01 0
Gleason 7.22 2.51-20.75 <0
PSA (ng/ml) 0.99 0.96-1.04 0
DKK-1 (high vs. low) 3.01 1.18-7.63 0
Abbreviations: CI = confidence interval; HR = hazard ratio.tissue or adjacent non-tumour tissue (Additional file 1:
Figure S1f). Patients with the high DKK-1 levels above
the median (38.4 ± 7.2 pmol/l) were found to have a sig-
nificantly shorter DSS (p = 0.031) and OS (p = 0.015)
than those with low DKK-1 levels (16.2 ± 7.5 pmol/l;
Figure 2). Univariate Cox regression analyses revealed
significant associations between OS and pT stage, lymph
node involvement, Gleason score and DKK-1 serum
levels (Table 3). There was no association for age and
PSA. An additional stepwise multivariate Cox propor-
tional hazard analyses revealed that high DKK-1 serum
levels were independently associated with a poor overall
survival (HR 3.73; 95%CI 1.44-9.66, p = 0.007 shown in
Table 3).
Discussion
High levels of DKK-1 expression in metastatic prostate
cancer tissue have been previously associated with a
poorer survival [8]. The role of serum DKK-1 levels inical characteristics and DKK-1 serum levels on overall
Multivariate analyses
alue HR 95% CI P value
.34 not included
01 8.76 1.85-41.47 0.006
.02 n.s.
.001 3.34 1.10-10.29 0.036
.93 not included
.02 3.73 1.44-9.66 0.007
Rachner et al. BMC Cancer 2014, 14:649 Page 5 of 6
http://www.biomedcentral.com/1471-2407/14/649localised prostate cancer patients has not been previ-
ously investigated. In line with earlier reports in prostate
cancer, we show an increased DKK-1 expression in pros-
tate cancer tissue compared to BPH [8]. In our TMA
analyses, no correlation between DKK-1 tissue expres-
sion in the primary tumour and patient survival was ob-
served. However, DKK-1 expression within the tumour
was very heterogeneous. Heterogeneity is a known find-
ing within prostate cancer lesions [11,12]. The hetero-
geneity of DKK-1 protein expression within the tumour
may limit the diagnostic value of DKK-1 assessment
from biopsies of the primary cancer and also explains
the lack of correlation between tumour and serum DKK-
1 levels. Assessment of circulating DKK-1 levels in pa-
tients at the time of diagnosis, prior to any therapy, re-
vealed that patients with low levels of DKK-1 had a
significantly better DSS and OS than those with high
DKK-1 levels. A limiting factor of our study is its
descriptive nature and the relatively small number of pa-
tients available for serum assessment. Larger prospective
trials should be performed to further validate the find-
ings presented here. However, there is increasing data
from preclinical studies suggesting that DKK-1 may have
direct effects on tumour proliferation and cell cycle.
High levels of DKK-1 promoted tumour progression [9],
and inhibition of DKK-1 decreased tumour burden in
prostate cancer [10]. A decreased tumour burden, fol-
lowing DKK-1 inhibition has also been observed in mul-
tiple myeloma [13]. Interestingly, when assessing DKK-1
serum levels in patients with prostate cancer (n = 80)
compared to benign prostate hyperplasia (n = 23), we did
not see a significant increase (25.3 ± 6.0 vs. 27.9 ± 12.9)
in DKK-1 values. This finding, together with the lacking
correlation between prostate cancer DKK-1 and DKK-1
serum levels could be explained by the hypothesis that
prostate cancer derived DKK-1 only modestly influences
DKK-1 serum levels. If this is the case, increased DKK-1
expression in non-tumour derived tissue, as seen in our
TMA, may have direct tumour promoting effects. There
are an increasing number of reports that suggest differ-
ent mechanisms by which DKK-1 may affect tumour
biology. These anti-tumour effects appear to be, at least
in part, independent of Wnt signaling and a role of
p21CIP-1/WAF-1 has been suggested [10]. Recently, DKK-
1 was reported to mediate tumour survival in osteosarcoma
cells, via the stress response enzyme ALDH1 [14]. In
addition, a negative correlation between DKK-1 serum
levels and prognosis has been suggested in non-small cell
lung cancer as well as cervical carcinoma [15,16]. These ob-
servations support the role of DKK-1 as a potential tumour
promoter and are fully consistent with our finding that
high circulating DKK-1 levels are associated with a worse
disease-specific and overall survival in prostate cancer pa-
tients. However, it remains unclear to what extent DKK-1serum levels are tumour derived, or if high levels of circu-
lating DKK-1 from other sites promote tumour growth
and/or resistance to therapy.
Conclusion
In conclusion, high levels of serum DKK-1 were associated
with a poorer overall survival in prostate cancer patient. In
light of anti-DKK-1-antibodies currently under clinical
evaluation for patients with advanced multiple myeloma,
these data warrant further research on the role of DKK-1 in
solid malignancies, including prostate cancer.
Additional file
Additional file 1: Figure S1. Distribution of DKK-1 staining score across
the evaluated prostate TMA (a). DKK-1 staining is separated according to
Gleason score (b) and the presence of lymph node involvement (c). DKK-1
tissue expression in the tumour is shown in relation to DKK-1 expression in
adjacent tissue (d), age (e) and DKK-1 serum levels. *p <0.05.
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